title: Aspirin-induced increases in soluble IL-1 receptor type II concentrations in vitro and in vivo.
abstract: This study examined the influence of low-dose aspirin on interleukin (IL)-1alpha , IL-1 receptor antagonist (IL-1ra), and soluble receptor type II (sIL-1RII) secretion in vivo and in vitro. Blood mononuclear cells were isolated from healthy young men who ingested 81 mg of aspirin on alternate days for 2 weeks and from unmedicated controls. Aspirin had minor effects on ex vivo secretion of IL-1beta and no influence on IL-1ra. In contrast, unstimulated ex vivo secretion of sIL-1RII was over twice as high by cells from aspirin-treated subjects (1115+/-123 vs. 460+/-77 pg/mL, P = 0.02). Lipopolysaccharide-stimulated sIL-1RII secretion was influenced similarly. Plasma sIL-1RII concentrations were 23% higher in aspirin-treated subjects (10.2+/-0.6 vs. 8.4+/-0.3 ng/mL, P = 0.03). In addition, cells from unmedicated subjects cultured in vitro with aspirin (10 microg/mL) secreted significantly greater amounts of sIL-1RII. Thus, low-dose aspirin therapy may prevent inflammation by increasing soluble receptor secretion, thereby preventing IL-1 from binding target cells.
authors.affiliation: Intercollege Physiology Program, Noll Physiological Research Center, Pennsylvania State University, University Park 16802-6900, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Daun
authors.forename: R W
authors.initials: RW
authors.lastname: Ball
authors.forename: H R
authors.initials: HR
authors.lastname: Burger
authors.forename: J G
authors.initials: JG
authors.lastname: Cannon
mesh_terms: D000328:Adult; D001241:Aspirin / Q000494:pharmacology*; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000187:drug effects; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D017472:Receptors, Interleukin-1 / Q000187:drug effects / Q000378:metabolism*; D053574:Receptors, Interleukin-1 Type II; D012795:Sialoglycoproteins / Q000378:metabolism; D012995:Solubility
chemical_list: C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D010975:Platelet Aggregation Inhibitors; D017472:Receptors, Interleukin-1; D053574:Receptors, Interleukin-1 Type II; D012795:Sialoglycoproteins; D001241:Aspirin